Live Breaking News & Updates on Vaccine Platform Biovaxys Technology Corp

Share this article
Share this article
PALM BEACH, Fla., Jan. 25, 2021 /PRNewswire/ Ovarian cancer is one of the most deadly gynecologic malignancy across the globe, but new treatments are gaining increased efficacy while displaying reduced toxicity. Clinical trials abound. Immunotherapy using immune-checkpoint modulators has been revolutionizing the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer. An article in Nature.com recently said that: The paramount achievement in cancer treatment in the last decade has undoubtedly been the introduction of T cell targeted immunomodulators blocking the immune checkpoints CTLA-4 and PD1 or PDL1… Anti-PD1/PDL1 antibodies have become some of the most widely prescribed anticancer therapies. T-cell-targeted immunomodulators are now used as single agents or in combination ....

United States , Tom Isett , Martinb Brenner , James Allison , Ken Kovan , Dror Harats , Tasuku Honjo , American Society Of Clinical Oncology , Contract Manufacturing Organization , Adamis Pharmaceuticals Corporation , Biovaxys Technology , Preclinical Program , Fn Media Group , Biovaxys Technology Corp , European Union , Vaccine Platform Biovaxys Technology Corp , American Cancer Society , Human Services , Us Department Of Health , Drug Administration , Bio Inc , Exchange Commission , Charles River Laboratories Inc , European Medicines Agency , Securities Exchange , Infinity Pharmaceuticals Inc ,